Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose atropine dose-finding study for myopia progression in children
2021-004884-29Phase 2Active
- Sponsor
- Pharma Stulln
- Start
- Jan 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atropine in myopia (5 arms), sponsored by Pharma Stulln. Primary endpoint: Change in myopia over 12 months. Started Jan 2022; status: active.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on 2021-004884-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004884-29.